Life-Science Tools · S&P 500
Danaher Corporation
Danaher is a large US life-science and technology company organized into three segments: Biotechnology, Life Sciences and Diagnostics. It owns more than 15 operating companies including Cytiva (bioprocessing), Beckman Coulter, SCIEX, Leica, Cepheid and Radiometer. FY2025 revenue was about $24.6 billion, with Diagnostics the largest segment at $9.9 billion and Biotechnology at $7.3 billion. Recurring sales such as consumables and services make up roughly 82% of revenue, and China accounts for about 11% of total sales. Bioprocessing demand recovered in 2025, lifting Biotechnology segment revenue 8.0%.
DHR Updated Jul 12, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Danaher Corporation is directly linked to 1 companies (0 supply, 1 revenue relationships) and reaches 2 companies within two hops; the links are backed by 5 dated sources, 3 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · approx. $24.6B (FY2025)
- Segments · Biotechnology · Life Sciences · Diagnostics
Revenue from
- 병원·임상검사실 (진단 소모품) High confidence· Revenue 9,941 USD_M · FY2025 · Diagnostics segment sales
The Diagnostics segment (Cepheid, Beckman Coulter, Radiometer) supplies clinical instruments, consumables and software to hospitals, physicians' offices, reference labs and critical-care settings. FY2025 Diagnostics revenue $9.94B, the largest of the three segments, 89% recurring.Confirms EN Danaher Investor Relations Published Jan 28, 2026: Danaher Reports Fourth Quarter and Full Year 2025 Results - 바이오의약품 제조사 (바이오프로세싱) High confidence· Revenue 7,293 USD_M · FY2025 · Biotechnology segment sales
The Cytiva/Pall bioprocessing business supplies chromatography resins, filters, cell-culture media and single-use hardware/consumables to pharma, biopharma and CDMOs. FY2025 Biotechnology segment revenue $7.29B (+8.0%), 88% recurring. Cytiva is specced into >90% of global mAb production volume.Confirms EN StockStory Published Oct 23, 2025: DHR Q3 2025 Deep Dive: Bioprocessing, Diagnostics, and Productivity Initiatives - 삼성바이오로직스 (싸이티바 바이오프로세싱) High confidence· Market share 90% · Cytiva coverage of global mAb production volume
CDMOs/biomanufacturers such as Samsung Biologics use Cytiva chromatography resins (MabSelect Protein A), purification filters and cell-culture media in commercial production. Cytiva leads the Korean resin/media market. Contract values not disclosed.Confirms KO The Korea Economic Daily Published Apr 10, 2025: Cytiva, a bioprocessing materials leader, launches two Protein A resins for antibody therapeutics
Pays to
- 전자·계측 부품 공급사 (장비 제조) Medium confidence
Danaher's manufacturing uses metallic-based components, electronic components and OEM products among other raw materials, sourced from a large number of suppliers worldwide with no single supplier material to the Company (10-K). Amounts not disclosed. - 화학·수지·플라스틱 원재료 공급사 (소모품·석유화학 기반) Medium confidence
Chemistries, plastics and other petroleum-based products feed consumables (resins, filters, reagents, media) and instrument manufacturing. Oil and gas prices indirectly affect freight, utilities and purchased-material costs (10-K). Amounts not disclosed.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| LigaChem Biosciences | lead2 | -26.2 | -18.1 | +37.1 | +151 | +60.5 | -40.7 |
| Samsung Biologics | lead1 | -6.8 | +8.6 | +5.8 | +28.7 | +5 | -20.1 |
| Danaher Corporation | node | +48.6 | -19 | -1.2 | -0.3 | +0.4 | -12.7 |
YTD as of 2026-07-10 · source: Yahoo Finance
An oligopoly life-science-tools company spanning bioprocessing (Cytiva), life sciences and diagnostics, with 82% of revenue in consumable/service recurring sales for high defensiveness. The thesis is the bioprocessing recovery — the Biotechnology segment turned to +8.0% in 2025, and Cytiva resins/media, specced into 90%+ of global mAb production, capture structural upside from drug and CDMO capacity expansion. Diagnostics ($9.9B), the largest segment, adds stability, while China (11% of sales) policy/procurement risk and the biotech investment cycle are the swing factors. In graph terms, CDMO expansion at players like Samsung Biologics transmits into Cytiva consumables demand.
Analysis generated from returns as of 2026-07-10